ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY 8-9 April 2011 Viareggio, Italy Chair: M. Aapro, CH
Dear Colleagues, The European School of Oncology is delighted that so many experts of lung, colorectal and breast cancer have accepted to be Faculty members of the «Gene Profiling in Oncology» course. The development of specific treatments, with an endocrine or other «target» is revolutionizing cancer treatment. We need to define the disease of the patient more precisely. Which parameters are of importance for the efficacy of the treatment? What should be asked from new methods? What do they bring today? Not all answers will come from the discussions at the meeting, but certainly there will be a lively debate! We look forward to your presence at this course. Matti S. Aapro Course chair
FACULTY M. Aapro IMO Clinique de Genolier, FMH Oncologie-Hématologie, Genolier, CH F. André Institut Gustave Roussy, Villejuif, FR D. Kerr University of Oxford, Clinical Pharmacology, UK J. Albanell Mestres Hospital del Mar, Barcelona, ES R. Labianca Ospedali Riuniti di Bergamo, IT L. Lacroix Institut Gustave Roussy, Villejuif, FR T. Le Chevalier Institut Gustave Roussy, Villejuif, FR H. Rugo UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US A. Sobrero Ospedale San Martino, Genoa, IT N. Thatcher The Christie NHS Foundation Trust, Manchester, UK G. Viale European Institute of Oncology, Milan, IT
FRIDAY, 8 APRIL 14:00 Introduction: Why has ESO organized this meeting? M. Aapro, CH WHERE DO WE STAND IN LUNG CANCER? 14:30 Treatment of advanced NSCLC: which drugs for which histology? And is histology reliable? T. Le Chevalier, FR 15:00 Do we know how to chose the best maintenance treatment? N. Thatcher, UK 15:30 New markers to define NSCLC and the potential of genomics L. Lacroix, FR 16:00 Coffee break WHERE DO WE STAND IN COLORECTAL CANCER? 16:30 What do we do today to chose targeted agents in metastatic CRC? Is k-ras mutation enough? What about b-raf? And how to decide between EGFR inhibitions and angiogenesis inhibition? R. Labianca, IT 17:00 Is T4,fewer than 12 lymph nodes and absence of MMR-D the standard to decide adjuvant chemotherapy in Stage II CRC? A. Sobrero, IT 17:30 Where are we with genomic testing in CRC? When should we use it? D. Kerr, UK 19:30 Dinner
SATURDAY, 9 APRIL WHERE DO WE STAND IN BREAST CANCER? 8:30 Classic pathology: why is proliferation difficult to determine? Why is not a standard? What was decided at St. Gallen last week! G. Viale, IT 9:00 Genomic evaluation: what are the data? F. André, FR 9:30 How to integrate the genomic tools in practice A panel discussion 10:00 Coffee break 11:00 Why genomic tools in endocrine-responsive tumours: a US perspective H. Rugo, US 11:30 Are genomic tools better than quantitative ER-reporting for determination of benefit of endocrine-therapy? C. Thomssen, DE 12:00 The Spanish experience J. Albanell Mestres, ES 12:30 But can my health system afford the cost? Speaker to be confirmed 13:00 Certificates of attendance and Lunch
GENERAL INFORMATION FOR MORE INFORMATION CONTACT European School of Oncology Via del Bollo, 4 20123 Milan, Italy Tel: +39 02 8546 4532 Fax: +39 02 8546 4545 Email: rventura@eso.net VENUE GRAND HOTEL PRINCIPE DI PIEMONTE Piazza Puccini, 1 55049 Viareggio, Italy Tel: +39 0584 4011 Website: www.principedipiemonte.com ATTENDANCE TO THE COURSE IS BY APPLICATION ONLY SUCCESSFUL APPLICANTS ARE GRANTED FREE REGISTRATION AND ACCOMMODATION APPLICATION DEADLINE: 28 FEBRUARY 2011 INFORMATION AND APPLICATION FORM AVAILABLE AT: WWW.ESO.NET HOW TO APPLY Interested participants should fill in the application form (www.eso.net or on request to rventura@eso.net) and send: Letter describing motivation for attending CV with a list of publications TRAVEL GRANTS A limited number of travel grants will be available. Requests for support should be submitted together with the application form by the application deadline. Travel grant will be awarded up to Euro 300,00. ACCREDITATION Application for CME recognition will be submitted to the Accreditation Council for Oncology in Europe. HOW TO REACH THE VENUE Viareggio is located on the Tuscan coast. The main airports to reach Viareggio are Pisa (20 Km) and Florence (80 km), both of which have regular national and international flight connections.